However, once GBM cells undergo chemotherapy and radiotherapy and maintain resistance to these treatments, FOXO3a overexpression exerts oncogenic function by increasing the expression of stem cell markers such as SOX2 [136]. This evidence concerns the gene FOXO3 and glioblastoma.